In May 2025, U.S. medical technology company Acclaro Medical completed a $23 million Series B financing round, led by Accelmed Partners with participation from Bencao Capital. The company’s core product, the Ultra Clear system, is the world’s first 2910 nm wavelength cold ablation fiber laser platform and has received FDA 510(k) clearance.¹, for the treatment of benign pigmented lesions, vascular lesions, and skin rejuvenation.

Traditional anti-aging treatments primarily rely on thermal lasers. When laser devices use high heat to ablate and remove epidermal imperfections, the depth of thermal diffusion exceeds 500 μm. This approach can pose latent risks to the dermis. For individuals with darker skin tones, the incidence of adverse reactions to such treatments is as high as 35%. This high rate of adverse events has led many patients to discontinue treatment.

The dermatology community has long sought methods to precisely control energy delivery to address skin aging. Acclaro Medical provides the answer: Ultra Clear.

Acclaro Medical boasts a core team that integrates medical expertise with engineering. Founder and Chief Technology Officer Shlomo Assa is a laser physicist who holds over 50 patents and previously served as Chief Engineer at the MIT Research Laboratory of Electronics.

Chief Medical Officer Eric F. Bernstein, a Professor of Dermatology at Harvard Medical School, led the global multicenter clinical trials for Ultra Clear. Chief Executive Officer Van Helen, formerly with Johnson & Johnson’s Medical Devices sector, successfully launched a product into 23 national markets within three years. Additionally, the company has assembled an advisory board comprising nine globally leading dermatologists.

While working at the MIT Photonics Laboratory, Shlomo Assa discovered that the 2910 nm wavelength exhibits extremely high absorption efficiency by water molecules, reaching up to 15 times that of traditional CO₂ lasers. This physical property implies that precise control of this wavelength band could enable "cold evaporation" at the cellular scale.

This discovery inspired Shlomo Assa to develop a cold laser platform.

The core advantages of Ultra Clear are its high efficiency, safety, and superior patient experience. According to the official website, the average treatment time for a full face is 15–30 minutes, with minimal bleeding during laser procedures and virtually painless sensation for patients.

During operation, the device delivers laser pulses to skin tissue with microsecond-level precision. The energy is instantaneously absorbed by water molecules and converted into vapor-phase micro-explosions, creating micro-channel pores with a diameter of only 120 μm in the epidermis. Clinical validation data show that the thermal damage zone is confined to 0.1 mm, equivalent to one-fifth of that associated with conventional lasers.

In a joint study conducted across seven medical institutions in the Eastern United States, the incidence of adverse reactions among patients with Fitzpatrick skin type VI decreased significantly. In 2024, Ultra Clear was awarded the “Safe Laser Treatment for All Skin Tones Award” by New Beauty magazine.

Ultra Clear works by removing the damaged epidermis and activating the vitality of the dermis.

First, the Ultra Clear laser microbeam performs precise ablation on the patient's epidermis. The laser beam accurately removes damaged epidermal cells, eliminating surface imperfections such as fine lines and pigmentation spots. Meanwhile, its cold laser characteristics confine thermal diffusion to the cellular level, significantly reducing pain and avoiding the risks of erythema and hyperpigmentation commonly associated with traditional lasers. Furthermore, beam homogenization technology ensures uniform energy distribution, achieving aesthetic-grade skin rejuvenation results.

Beyond epidermal renewal, deeper bioactivation occurs within the dermis. As laser energy penetrates to the mid-dermis, it creates controlled microthermal zones, where thermal stimulation activates the skin’s self-repair system. By stimulating fibroblast activity, this process synchronously promotes the endogenous production of three core youth-associated substances: Type I and III collagen (thickening the dermal matrix), elastic fibers (restoring skin tension), and hyaluronic acid (enhancing moisture retention and radiance), thereby reconstructing a healthy skin framework from the basal layer.

For deeper skin concerns, the 3DMIRACL system integrated into Ultra Clear precisely controls a 2910nm fiber laser, delivering thermal energy and cold laser directly to the dermis to stimulate collagen regeneration and achieve skin rejuvenation.

3DMIRACL is currently the world’s only fiber laser platform operating at a wavelength of 2910 nm. Its cold fiber delivery system vaporizes the target epidermal layer within a picosecond-level time window, strictly limiting the depth of thermal diffusion to less than 30 μm.

Furthermore, the system simultaneously triggers hemoglobin denaturation to form precise microcoagulation bands. This coagulation mechanism reduces the risk of secondary infection and creates a safe operational space for deep skin reconstruction.

The advantage of 3DMIRACL lies in its high-quality beam and extremely small spot size. This precision effectively eliminates the issue of uneven energy distribution common in conventional lasers, achieving high-definition and highly uniform skin smoothing results.

Another major advantage of the small spot size is its ability to safely target deeper skin layers, allowing the micro-channels created by the laser to close rapidly, which results in less pain and faster healing.

3D Intelli Pulse is the intelligent pulse system integrated into 3DMIRACL. This system enables precise three-layer processing:

• l Gentle CLEAR mode renews 15% of the stratum corneum

• l The more powerful CLEAR+ mode penetrates 80% of the epidermal depth, repairing acne scars and photoaging spots within 72 hours

• l The ULTRA mode penetrates directly into the dermis, stimulating Type I collagen synthesis to physically smooth out deep wrinkles within two weeks.

Schematic Diagram of Intelligent Pulse Technology Principle

In 2025, Ultra Clear adopted the advanced Laser-Coring technology to further promote skin repair. This technology employs a dual mechanism of "tissue coring + laser regeneration," creating collagen regeneration channels approximately 400 μm in diameter deep within wrinkles or scars. The core advantages of Laser-Coring are its combined therapeutic effects, reduced consumption, and personalized customization.

Preliminary studies have demonstrated that the combination of tissue coring and laser regeneration produces a synergistic effect, achieving cosmetic outcomes through rapid contraction of tissue in the treatment area. As this system establishes laser microchannels exclusively within the lesional tissue, energy delivery is concentrated on the core pathological region. Compared with full-thickness vaporization therapy, this approach effectively reduces ineffective energy dispersion and lowers the cost of consumables per treatment session.

Furthermore, Laser-Coring can be integrated into the Ultra Clear skin rejuvenation treatment protocol, allowing patients to customize their treatment plans based on their individual skin conditions. Patients can independently select parameters such as energy level, ablation depth, and coagulation level. Whether for mild exfoliation or deep collagen remodeling, Ultra Clear meets diverse clinical needs.

The 2910 nm cold fiber platform can simultaneously activate epidermal renewal and dermal remodeling. This characteristic gives it an irreplaceable competitive advantage in anti-aging therapies.

After former Johnson & Johnson executive Van Helen assumed the role of CEO, she integrated the IRS Section 179 tax deduction mechanism into the procurement system, directly reducing clinic acquisition costs by 30%. Furthermore, the company’s consecutive two-year win of the “Best Laser Treatment for All Skin Tones” award from *New Beauty* has helped bolster its premium, professional brand image.

Milestone Events

At the 2023 Annual Meeting of the American Society for Laser Medicine and Surgery, Bernstein presented 24-month study results showing that the incidence of fibrosis in patients treated with the ULTRA mode was 0.8%, significantly lower than the 2% regulatory alert threshold. Furthermore, the R&D team is leveraging three-dimensional elastography to establish an objective, quantifiable metric system that supplements traditional visual assessment.

Acclaro Medical has successfully transformed the “photothermal effect”—once confined to laboratories and renowned for its precision—into a universally applicable anti-aging solution through breakthroughs in core technologies, achieving a unity of safety and efficacy in the field of anti-aging.

Through technological innovation, Acclaro Medical transforms precise photothermal effects into standardized clinical protocols, making affordable, anti-aging treatments suitable for all skin tones a reality.

Source:

1.FDAOfficial Website,510(k)No.:K221385